Femasys Inc
NASDAQ:FEMY

Watchlist Manager
Femasys Inc Logo
Femasys Inc
NASDAQ:FEMY
Watchlist
Price: 1.24 USD 14.81% Market Closed
Market Cap: 33.7m USD

Femasys Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Femasys Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Femasys Inc
NASDAQ:FEMY
Pre-Tax Income
-$18.8m
CAGR 3-Years
-36%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Pre-Tax Income
$2B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
3%
Boston Scientific Corp
NYSE:BSX
Pre-Tax Income
$2.3B
CAGR 3-Years
28%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Pre-Tax Income
$3.5B
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
12%
Abbott Laboratories
NYSE:ABT
Pre-Tax Income
$7B
CAGR 3-Years
-5%
CAGR 5-Years
11%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Pre-Tax Income
$2.7B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
17%

Femasys Inc
Glance View

Market Cap
33.7m USD
Industry
Health Care

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.

FEMY Intrinsic Value
2.26 USD
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Femasys Inc's Pre-Tax Income?
Pre-Tax Income
-18.8m USD

Based on the financial report for Dec 31, 2024, Femasys Inc's Pre-Tax Income amounts to -18.8m USD.

What is Femasys Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-11%

Over the last year, the Pre-Tax Income growth was -32%. The average annual Pre-Tax Income growth rates for Femasys Inc have been -36% over the past three years , -11% over the past five years .

Back to Top